Clinical Trial

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in healthy adult volunteers.
Protocol Amendment History 3 changes
notable Enrollment increased: 40 -> 64 participants 2026-07-29
minor Trial arms changed: 5 -> 8 2026-07-29
critical Recruitment opened 2026-06-02
Trial Details
NCT Number NCT07527221
Lead Sponsor Eilean Therapeutics AU Pty Ltd
Conditions Healthy Volunteers
Enrollment 64 participants
Start Date 2026-04-16
Primary Completion 2026-11 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-28